Background. Maternal and fetal outcomes associated with botulism and botulinum antitoxin use during pregnancy and the postpartum period have not been systematically reviewed.
Approximately 100-150 cases of botulism occur in the United States annually [1] . Botulism is a life-threatening neuromuscular disease caused by exposure to toxin produced by Clostridium botulinum, a spore-forming, anaerobic, gram-positive bacillus [2] . All forms of botulism (foodborne, infant, wound, iatrogenic, and adult intestinal colonization) can result in progressive toxin-induced paralysis of skeletal muscles, which can lead to respiratory failure and death [3, 4] . Botulism is diagnosed clinically, based on the presence of neuromuscular deficits that most often begin with cranial nerve paralyses. Clinicians should be aware of the symptoms of botulism and consider the diagnosis when a patient presents with acute onset of neuromuscular deficits.
The United States government categorizes botulinum toxin as a Tier 1 bioterrorism agent, the highest threat level for possible biologic threats [5] . The United States government stockpiles a heptavalent botulinum antitoxin for the treatment of botulism; administration of antitoxin soon after symptom onset can impede the progression of toxin-induced paralysis. The Centers for Disease Control and Prevention (CDC) maintains a 24/7 botulism clinical consultation service.
Because botulism can affect pregnant and postpartum women, it is important for women's healthcare providers to know the signs and symptoms and treatment options. We conducted a systematic review of the literature to address the following questions: (1) Are pregnant and postpartum women more susceptible than nonpregnant women to botulism? (2) Do pregnant women experience a different clinical presentation or more severe disease than nonpregnant patients? (3) Is there an increased risk of adverse maternal, fetal, or neonatal outcomes associated with botulism? (4) What are the effects of antitoxin treatment when administered to pregnant women?
METHODS

Sources
We searched the following databases: Embase, Global Health, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, Scopus, and Medline from inception through May 2015 to identify all listed publications using search terms established in conjunction with an expert CDC librarian: ("botulism" or "botulinum toxin") and ("pregna*" or "matern*" or "postpartum" or "puerperal" or "fetal" or "fetus" or "neonate" or "newborn" or "abort" or "uterus"). We identified 4517 articles through this search and used EndNote to create a bibliography of citations and abstracts for review. We also contacted 4 botulism experts at the CDC who reviewed their personal libraries to identify any additional articles not captured by the search. The National Botulism Surveillance System at CDC was reviewed to identify any additional cases of botulism during pregnancy. Additionally, we contacted authors of several case reports in which the clinical information was limited. Fortyseven foreign articles were screened by native speakers and formally translated.
Study Selection
The minimum criteria for articles were the presence of at least 1 case of botulism reported during pregnancy or the postpartum period (within 6 weeks after delivery). For purposes of inclusion in our review, the diagnosis of botulism was established based on authors' report, irrespective of the availability of reported clinical or laboratory data. Articles describing botulinum toxin use during pregnancy and the postpartum period were also reviewed to search for cases of iatrogenic botulism following cosmetic or therapeutic use of botulinum toxin. Articles chosen for inclusion were limited to reports or studies of human cases; animal studies were excluded. Abstracts, case reports, case series, observational cohort studies, and surveillance or outbreak reports were reviewed. Non-English articles were assessed by title and abstract, screened by a native speaker of the language of the report to determine whether primary data were reported, and professionally translated when determined to include primary data. We excluded duplicate reports. Reports on cosmetic or therapeutic use of botulinum toxin during pregnancy that did not result in botulism were not included as part of the systematic review. We also excluded unpublished reports, review articles, and policy briefs; however, we reviewed these articles to identify any additional sources of primary data through reference searching. Two reviewers (B. H. R. and D. M. D.) screened titles and abstracts and selected those that contained clinical data on botulism among pregnant or postpartum women for full-text review. Conclusions reached by the 2 reviewers on whether an article merited a full-text review were compared, and discrepancies were resolved in favor of full-text review. Data were abstracted in triplicate using a Microsoft Office Excel database adapted from a template for systematic reviews of other biologic threats. Complete concordance of data abstraction elements was achieved between reviewers through multiple reviews and discussion. Data elements extracted from the articles included (1) gestational age at the time of diagnosis; (2) gestational age at the time of delivery; (3) geographic location of case; (4) source of toxin exposure; (5) method of diagnosis; (6) clinical presentation; (7) intubation/ventilation status and duration of ventilation; (8) type of antitoxin and the timing of administration; (9) maternal and obstetric outcomes, including mode and timing of delivery; and (10) fetal or neonatal outcome.
Tabulation, Integration, and Results
The database searches and review of references identified 4517 articles (Figure 1 ). After full-text review, 18 articles met the inclusion criteria, from which we identified 17 case reports (2 articles described the same case) ( Table 1 ) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . The search also identified 25 articles that reported the use of commercially available botulinum toxin (eg, Botox) for cosmetic and therapeutic indications (eg, treatment of wrinkles, achalasia, migraines, and cervical dystonia) during pregnancy; however, none of these uses resulted in botulism, and no associated adverse maternal, fetal, or neonatal outcomes were reported . Therefore, we excluded these reports. We did not identify any randomized controlled trials or cohort studies in our systematic review.
Of the 17 cases of botulism reported among pregnant and postpartum women [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , 8 occurred in the United States [8-11, 13, 16, 20, 22] . Other locations included Spain [12, 21] , Canada [15, 18, 19] , Russia [7] , Argentina [6] , Germany [14] , and Armenia [17] . Articles describing cases were published from 1955 through 2012; 4 years or fewer lapsed between the year of diagnosis of a case and the year of publication for 10 cases. In 7 of the cases, the exact year of the case was not stated [6, 8, 12, [14] [15] [16] [17] . Maternal botulism cases were reported during all trimesters of pregnancy: 2 cases occurred in the first trimester, 3 in the second trimester, and 11 in the third trimester. Only 1 case in the postpartum period was described [22, 23] . Alternate diagnoses considered during evaluation included Guillain-Barré syndrome, myasthenia gravis, organophosphate poisoning, and mushroom intoxication.
Of the 16 cases of prenatal botulism, 5 cases were epidemiologically linked to food suspicious for contamination (eg, homecanned green beans, canned fish) [6, 12, 14, 20, 21] , 5 resulted from exposure to foods with laboratory-confirmed botulinum toxin [8, 13, 15, 18, 19] , 2 resulted definitively from wounds contaminated with C. botulinum [11, 16] , and in 4 cases, the exposure was unknown [7, 9, 10, 17, 22, 23] . The postpartum case, also of unknown exposure, was a suspected wound contamination with C. botulinum identified 5 days after a cesarean delivery [22, 23] . Laboratory testing identified C. botulinum in clinical specimens of 9 patients: 6 in serum specimens, 2 in wound specimens, and 1 in a stool specimen [9-11, 13, 14, 16, 22, 23] . Botulinum toxin serotypes identified included serotype A, B, and E (Table 1) The signs and symptoms of botulism described in these case reports included nonspecific gastrointestinal symptoms, cranial nerve paralysis, muscle weakness, and respiratory compromise. The clinical presentation was described in 15 of the cases. The most common symptoms were diplopia or blurry vision in 13 (86%) cases, peripheral muscle weakness in 12 (80%) cases, and respiratory difficulties in 12 (80%) cases. Nine of the patients (>50%) reported nausea or vomiting, and 7 (47%) experienced difficulty swallowing. About one-third of the patients reported dry mouth or sore throat, dysphonia, changes in hearing or nasal speech, and hoarseness. Eleven women had progressive neurologic deficits and respiratory failure that required admission to an intensive care unit (ICU) [6, 9-12, 14-17, 19, 22, 23] . Two pregnant patients died of respiratory failure [9, 20] . Another pregnant patient and the postpartum patient were reported being in a persistent vegetative state [17, 22, 23] .
One woman died suddenly of progressive respiratory failure at the end of her seventh month of pregnancy. Because her death was unexpected, cesarean delivery could not be performed in time, so her fetus also died [20] . One patient who was 6 weeks pregnant underwent dilatation and curettage following a spontaneous miscarriage [14] . No neonatal deaths were reported. Among the 12 pregnancies with information about outcome, 6 were preterm deliveries [6, 9-11, 16, 17] . Four of these were medically indicated due to maternal decompensation [6, 11, 16, 17] . Four preterm neonates required admission to the neonatal ICU [9] [10] [11] 16] , including 1 preterm infant whose delivery was associated with a placental abruption [10] . No description of the etiology for the placental abruption was provided in the case report. We found no reports of congenital botulism or of neonates or infants born to these mothers having neurologic symptoms consistent with exposure to botulinum toxin.
The 2 patients who received antitoxin within the first 72 hours of symptom onset had better outcomes than those who received antitoxin later; 1 fully recovered and was discharged from the hospital [13] , and the second required a tracheostomy due to acute respiratory failure but recovered within 15 days after symptom onset [19] . Both patients remained pregnant and had uncomplicated vaginal deliveries at term. Nine patients received antitoxin either ≥72 hours after symptom onset or the timing was not stated [6, 7, 9-12, 14, 16, 17] . Six of these required intubation, with 4 of them requiring long-term ventilation and tracheostomy placement. One woman who received antitoxin on the fourth day of symptoms had worsening symptoms of respiratory failure, which did not respond to intubation and aggressive supportive care; she died 13 days after the onset of symptoms [9] . One woman whose botulism led to a chronic vegetative state was reported to have received antitoxin, but timing of administration was not stated [17] . For the woman who was reported to have postpartum botulism, which progressed to a chronic vegetative state, antitoxin administration was not mentioned [22, 23] . Limited information is available about birth outcomes.
DISCUSSION
To the best of our knowledge, this is the first systematic review of botulism in pregnancy. Knowing the clinical manifestations, course, and treatment of botulism is important for healthcare providers of pregnant and postpartum women. We found that early identification and treatment of botulism can minimize adverse maternal and perinatal outcomes. Signs and symptoms of botulism among pregnant women were the same as those among nonpregnant women [53] . No pregnancy-associated neurologic disease mimics the clinical picture of botulism, and we have no reason to believe that conditions commonly confused with botulism (eg, Guillain-Barré syndrome and myasthenia gravis) would occur with greater frequency among pregnant than nonpregnant women. Thus, signs and symptoms suggestive of neuromuscular dysfunction should prompt consideration of botulism in the differential diagnosis [2] . Because pregnant women have decreased functional residual lung capacity and increased oxygen consumption, rapid progression to respiratory failure may occur. While foodborne exposure is the most common cause of maternal botulism, other sources of exposure can occur, such as wound infections associated with injection drug use or cesarean delivery. Thorough assessment of epidemiologic risk factors, such as high-risk food exposures or intravenous drug use, combined with a high clinical suspicion for any pregnant or postpartum women with cranial nerve deficits or neuromuscular weakness, can lead to early recognition and treatment.
Botulinum antitoxin neutralizes toxin and may decrease the need for intubation, ventilation, and long-term hospitalization [49] . The 2 pregnant patients who received botulinum antitoxin within 72 hours of onset recovered fully and had uncomplicated, full-term deliveries [13, 19] . Previous studies of nonpregnant patients support the early administration of antitoxin, which can halt the progression of symptoms and severity of disease [54, 55] . Because our review of pregnant patients found no adverse perinatal outcomes with antitoxin use, this evidence supports the early administration of antitoxin to pregnant women, when possible [49] .
Our literature review did not identify any adverse effects for mother or infant from the use of botulinum toxin in therapeutic doses for medical and/or cosmetic purposes. Although no formal human studies have been conducted, observational data of 25 cases from this review on botulinum toxin used at therapeutic doses for medical and/or cosmetic purposes are reassuring. There are insufficient data to determine if pregnant or postpartum women are more susceptible to botulism than nonpregnant individuals. In the event of a botulism outbreak involving pregnant women, data regarding gestational age, severity of clinical course, and pregnancy outcomes should be captured.
In this review, many of the pregnant and postpartum patients required ventilation and close monitoring of their respiratory status. Compared to nonpregnant women, pregnant women may be at increased risk for difficult intubation, intubation failure, aspiration, and admission to the ICU [50] . Obstetricians and other healthcare professionals may anticipate the possible need for intubation and ventilation among pregnant women presenting with neuromuscular deficits thought to be due to botulism. The patient's healthcare team may also need to consider obstetrical interventions, such as antenatal corticosteroids to enhance fetal lung maturity and improve neonatal outcomes [51] , for pregnant women who present with botulism prior to term. Additionally consultation with specialists in maternal-fetal medicine, pulmonary care, or critical care can be considered to assist with clinical management.
This review did not identify any cases of congenital botulism. The botulinum toxin, which weighs approximately 150 kDa, has been described as being too large to cross the placenta [52] . The 2 cases describing first-trimester botulinum exposure did not provide sufficient data to draw conclusions about maternal-fetal transmission of the toxin or risk of congenital anomalies [14, 18] . Botulism was associated with preterm delivery in at least 6 cases of botulism in this review, but most of these deliveries were induced because of maternal decompensation; therefore, it is not known if botulism during pregnancy increases the risk for preterm labor.
This systematic review provides a thorough summary of the literature regarding botulism in pregnancy and the postpartum period. The strength of our review is that it represents a broad search of the literature and includes both English and non-English publications. While the number of reported cases is small, this review may be useful to guide clinical recommendations for naturally occurring botulism or bioterrorist-related botulism during pregnancy. A major limitation of this systematic review is that it relies on a small number of case reports of botulism during pregnancy and only 1 case report of a woman in the postpartum period. No prospective cohort or randomized control trials are available and, given the severe morbidity and potential mortality, these are unlikely to be conducted. Additionally, given the small number of cases, we could not assess trimester-specific risks.
The clinical manifestations and risks of botulism during pregnancy and the postpartum period are important for women's healthcare providers to be aware of. Botulism is on the differential diagnosis for any pregnant or postpartum woman who presents with a sudden onset of neuromuscular deficits. This includes cranial nerve paralyses that manifest with symptoms of dysarthria, dysphagia, and diplopia. A high level of clinical suspicion is key for early diagnosis and treatment of botulism. If the diagnosis of botulism is suspected during pregnancy or the postpartum period, botulinum antitoxin should be administered to the patient as early as possible. Health departments can be contacted 24/7 for suspected cases of botulism; CDC performs clinical consultations and facilitates emergent delivery of antitoxin after notification from health departments. Additionally, healthcare providers can make preparations for possible intubation, obstetrical monitoring, and delivery because maternal botulism may lead to spontaneous or medically indicated preterm delivery.
Notes
